chang earn forecast
life scienc demand cluster remain solid
transpar gain invest arm visibl
account chang confer call messag
surround market fundament continu posit
research fund part equat remain intact new omnibu
spend bill alloc addit billion nih budget
approxim billion fda focus expedit approv
high efficaci drug manag addit highlight
fact medic research philanthropi set all-tim high
billion global commerci also hit record high us
ventur capit fund life scienc hit record
billion san francisco boston compani captur largest
share new fund note compani startup
captur new drug approv clear driver
big pharma establish ventur arm acquir compani
establish partnership would enhanc pipelin
ventur arm compani start
invest ventur group came focu quarter new
account rule requir compani record gain
invest visibl mark market entiti report
requir incorpor valu
half invest cost either publicli trade
visibl mark provid transpar million
embed gain cost basi portfolio
accret balanc invest
remain half still balanc sheet cost import note
portfolio diversifi repres hold averag
cost million invest repres non-ten
privat entiti singl largest gain invest
seri round invest googl
highlight arm real differenti client tenant
importantli enabl compani understand scienc
go financi gain group obvious primari focu
insight underwrit tenant also import benefit final
alexandria ventur invest part also help compani
distinguish better posit align grow
compani turn respect knowledg base
meaning presenc life scienc ecosystem
attract risk profil solid balanc sheet well-leas
develop pipelin total gross real estat asset
develop target current net debt adjust
ebitda ttm averag target
million squar feet pipelin construct
leas end
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
estimates/valu revis estim reflect result updat
assumpt ffo estim increas slightli
forward nav/sh estim blend cap rate
higher noi invest pt goe price target
weight combin dcf forward affo multipl affo
basi share trade affo estim versu offic sector
discount impli cap vs sector averag mc weight
higher oper margin tradit offic reit gener favor
intern extern growth outlook time opinion stand distinctli
pack compani pure play nich offic reit focus life scienc
technolog campus select urban cluster suppli remain constrain solid
core portfolio growth embed develop pipelin posit compani
rel favor ss noi growth outlook versu sector
take report report solid result ffo adjust
per share repres strong increas yoy ffo
result ahead estim street consensu driver posit
varianc versu estim lower interest expens ss cash noi
strong driven strong mark market leas renew well burn free
rent project ss noi basi compar
store revenu vs
big deliveri quarter place servic townsend stripe
headquart spectrum brannan street pinterest
dexter total project open full
quarter contribut develop contribut strong result leas
spread cash overal strong result
strong ss noi leas spread annual ffo guidanc tighten rais
midpoint worth note account chang provid transpar
embed valu invest portfolio show embed gain million
impli invest gain invest observ
notabl leas activ leas million squar feet vs million
squar feet million leas execut quarter includ
third street mission bay sf sorrento three
life scienc entiti binney cambridg verili sf sf
execut leas south san francisco
highlight quarter
 report ffo vs estim street consensu
 ss noi cash vs year ago
 same-stor revenu expens versu
prior quarter
 occup slightli
 oper margin flat
 leas volum sqft vs prior quarter sqft
 leas spread renew basi cash
guidanc ffo guidanc tighten rais midpoint
current consensu vs estim
second avenu
third street
price target calcul base combin forward multipl forward dcf
risk includ interest rate overal macroeconom environ
articl articl
time dissemin may et
analyst sheila mcgrath wendi primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
